Canterbury DHB


Introduction and Key Questions

All patients should be considered for entry into clinical trials when available. See the Clinical Trials page on the Intranet.

Key questions to be answered before giving intensive treatment to a newly diagnosed patient with ALL:

The following important differences exist when ALL is compared to AML:

About this Canterbury DHB document (8848):

Document Owner:

Peter Ganly (see Who's Who)

Last Reviewed:

November 2018

Next Review:

November 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 8848